St. Jude Children’s Research Hospital Clinical Trial Results Reduce Rate of Relapse for Children with Acute Lymphoblastic Leukemia (ALL)

St. Jude Children’s Research Hospital Clinical Trial Results Reduce Rate of Relapse for Children with Acute Lymphoblastic Leukemia (ALL)

St. Jude Children’s Research Hospital concluded the Total Therapy Study 16 evidencing the ability to successfully reduce the rate of central nervous system (CNS) relapse to 1.8% for acute lymphoblastic leukemia (ALL) in children. The Problem: ALL Relapse Despite...
Rutgers Cancer Institute of New Jersey Secures Grants & Pursues T-Cell Acute Lymphoblastic Leukemia

Rutgers Cancer Institute of New Jersey Secures Grants & Pursues T-Cell Acute Lymphoblastic Leukemia

Rutgers Cancer Institute of New Jersey received over $2 million in grants recently to study potential treatment targets for a rare and aggressive blood cancer called T-cell acute lymphoblastic leukemia (T-ALL). The recent grant awards were reported by Rutgers Cancer...
Chinese Research Reveals Sequential Infusion of Humanized CD19-Modified & CD22-modified  CAR-T Cells Aid Relapsed ALL

Chinese Research Reveals Sequential Infusion of Humanized CD19-Modified & CD22-modified  CAR-T Cells Aid Relapsed ALL

DovePress reports a group of Chinese universities note CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and re-infusion of CAR-T cells is not always...

Pin It on Pinterest